Medtronic (NYSE:MDT) announced today that it submitted 510(k) applications to the FDA seeking clearance for an interoperable insulin pump. Clearance would enable system integration with a continuous glucose monitor (CGM) sensor based on Abbott’s most advanced platform. This marks the latest development in a landmark collaboration between the two medtech giants. Last summer, the companies […]
Medtronic
Medtronic wins FDA nod for new Simplera Sync CGM with MiniMed 780G
Medtronic (NYSE:MDT) announced that the FDA approved its Simplera Sync continuous glucose monitor for use with the MiniMed 780G. Approval provides more options for users of the automated insulin delivery (AID) system, which can also work with the Guardian 4 sensor. Simplera Sync, a disposable, all-in-one sensor requires no fingersticks or overtape. It works with SmartGuard […]
Doctors issue call to action to eliminate barriers to automated insulin delivery
Key opinion leaders issued a call to action to the diabetes community to recognize the importance of automated insulin delivery (AID). A number of doctors issued this call, published by Mary Ann Liebert’s Diabetes Technology & Therapeutics, to implement the advances made in the AID technology space. They say pivotal trials and real-world data support […]
Medtronic has a new leader in its Diabetes unit
Medtronic (NYSE:MDT) has appointed a former Dexcom leader as the new head of Americas for its Diabetes business unit. On LinkedIn, Laura Endres said in a post that last week was her first with the medtech giant’s Diabetes unit. She spent more than a decade at continuous glucose monitor (CGM) maker Dexcom, bringing significant diabetes […]
The biggest diabetes tech news out of ATTD 2025
Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]
Medtronic reports first real-world data on smart insulin pen system
Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination. The data evaluated Medtronic’s Smart MDI system, which combines the InPen with the Simplera continuous glucose monitor (CGM). Data showed how the system, designed for people with diabetes using multiple daily injections (MDI) when used as intended, […]
Data supports Medtronic Prevail paclitaxel-coated balloon
Medtronic (NYSE: MDT) announced results from a registry highlighting the effectiveness of the Prevail drug-coated balloon (DCB). Dr. Sacharias von Koch of the dept. of cardiology and clinical sciences at Lund University, Skåne University Hospital in Sweden presented findings from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) at Cardiovascular Research Technologies (CRT) 2025 in […]
Medtronic enrolls first patient in drug-coated balloon study
Medtronic (NYSE: MDT) announced today that investigators enrolled the first patient in a pivotal trial of its Prevail drug-coated balloon (DCB). The study evaluates the paclitaxel-coated balloon catheter for in-stent restenosis (ISR) and de novo small vessel disease. Dr. Ziad Ali, director of the DeMatteis Cardiovascular Institute at St Francis Hospital & Heart Center (New […]
Data outlines need for CGM study design guidelines
A study looking at three leading continuous glucose monitors (CGMs), including systems from Abbott and Dexcom, signaled the need for new guidelines, investigators say. Published in the Journal of Diabetes Science and Technology, the study evaluated the latest-generation Abbott FreeStyle Libre 3, Dexcom G7 and Medtronic Simplera CGMs against different comparator methods and during clinically […]
Medtronic seeks to expand MiniMed 780G label to type 2 diabetes, submits new CGM to FDA
Third-quarter results for Medtronic (NYSE:MDT) today included a timeline for a planned label expansion for its automated insulin delivery platform. The medtech giant posted an overall revenue miss for the three months, despite growth in the Diabetes business. (Read more about the company’s third-quarter results at sibling site MassDevice.) Speaking on the company’s earnings call […]
